Related by context. All words. (Click for frequent words.) 79 Phase Ib II 78 phase IIa 78 multicenter Phase 78 Phase Ib clinical 77 Phase Ib 77 phase IIb 77 placebo controlled Phase 76 Phase 2a trial 76 Phase Ib study 76 multicenter Phase II 76 Phase #b/#a 76 dose escalation Phase 76 blinded randomized placebo controlled 75 Phase 1b 75 BRIM3 75 phase IIa clinical 74 ADVANCE PD 74 dose escalation trial 74 randomized controlled Phase 74 Phase 2a 74 phase IIb clinical 74 Phase 1b clinical 74 Phase 1a clinical 74 alvespimycin 74 Phase 1a 73 LUX Lung 73 riociguat 73 Initiated Phase 73 Phase IIIb clinical 73 BRIM2 73 phase IIb study 73 Phase 2a clinical 73 phase IIb trial 73 phase 2a 73 Phase 2b study 73 forodesine 73 Phase 2b trial 73 Phase IIa trial 73 multicenter randomized Phase 73 multicenter phase 73 dose escalation clinical 72 Phase 1b trial 72 pharmacokinetic PK study 72 APEX PD 72 neratinib 72 MAGE A3 ASCI 72 HuMax EGFr 72 Tarceva TM 72 ongoing Phase 1b 72 pharmacokinetic PK 72 Phase IIa 71 Cloretazine ® 71 Aplidin 71 double blinded placebo 71 fosbretabulin 71 Phase III 71 phase Ib clinical 71 MERLIN TIMI 71 Phase #/#a 71 phase IIIb 71 ELACYT 71 receptor tyrosine kinase inhibitor 71 Initiate Phase 71 midstage clinical 71 HCV SPRINT 71 dosing cohort 70 ganetespib 70 lintuzumab 70 NO# [002] 70 treatment naive genotype 70 placebo controlled clinical 70 VNP#M 70 Phase IIb trials 70 dose escalation phase 70 dose cohort 70 Phase Ia 70 randomized Phase 2b 70 relapsed MM 70 multicenter randomized placebo controlled 70 elotuzumab 70 registrational 70 Zemplar Capsules 70 HGS# 70 dose dose escalation 70 initiated Phase Ib 70 registrational trial 70 AEG# 70 Phase IIIb 70 SUCCEED trial 70 randomized multicenter trial 70 ascending dose 70 placebo controlled Phase III 70 rALLy clinical trial 70 randomized Phase IIb 70 Phase IIB 70 Phase III placebo controlled 70 IIa trial 70 enzastaurin 70 Phase IIa clinical 70 Cloretazine 70 Bayer HealthCare Onyx Pharmaceuticals 70 Phase III clinical 70 Omacetaxine 70 REVIVE Diabetes 70 Phase Ib clinical trials 70 Phase IIA 70 tramiprosate Alzhemed TM 70 galiximab 70 Phase 1b clinical trials 70 Phase III psoriasis 69 oral prodrug 69 HGS ETR1 69 nab paclitaxel 69 Phase II 69 TMC# C# 69 HGS ETR2 69 Pivotal Phase III 69 DASISION 69 confirmatory clinical 69 oral methylnaltrexone 69 Phase IIb III 69 double blinded randomized 69 Panzem R NCD 69 brivaracetam 69 GSK# [001] 69 Aflibercept 69 dose escalation 69 CRMD# 69 rALLy trial 69 pharmacodynamic PD 69 INCB# [001] 69 thorough QT 69 Phase 2b clinical 69 mg/m2 cohort 69 Randomized Phase 69 sunitinib malate 69 maximally tolerated dose 69 Phase IIb clinical trials 69 Cloretazine R VNP#M 69 Pivotal Phase 69 pivotal bioequivalence 69 axitinib 69 pomalidomide 69 evaluating tivozanib 69 ixabepilone 69 Amrubicin 69 XL# SAR# 69 pertuzumab 69 paclitaxel poliglumex 69 Phase IIb 69 IIa clinical 69 BAY #-# 69 blinded placebo controlled 69 oral ridaforolimus 69 torezolid phosphate 69 budesonide foam 69 Phenoptin 69 RSD# oral 68 AIR CF2 68 velafermin 68 GLP toxicology studies 68 confirmatory Phase III 68 viral kinetic 68 pharmacokinetics PK 68 Traficet EN 68 randomized Phase III 68 Exherin TM 68 Phase III multicenter 68 YONDELIS 68 multicenter Phase III 68 DermaVir Patch 68 Phase IIb trial 68 OvaRex ® MAb 68 Ophena TM 68 NP2 Enkephalin 68 mertansine 68 Phase 2a clinical trials 68 Phase III Pivotal 68 Phase III randomized controlled 68 PXD# 68 R#/MEM # 68 STRIDE PD 68 farletuzumab 68 GALNS 68 randomized multicenter 68 evaluating Xcytrin 68 phase IIb III 68 Onrigin 68 Annamycin 68 CBLC# 68 AVADO 68 trastuzumab DM1 68 Prostate AdenoCarcinoma Treatment 68 tolerability pharmacokinetics 68 visilizumab 68 azilsartan medoxomil 68 Phase IIa trials 68 HCD# [002] 68 randomized discontinuation trial 68 viral kinetics 68 multiple ascending dose 68 dose escalation study 68 APPRAISE 68 Dacogen injection 68 adecatumumab MT# 68 Phase IIb clinical 68 Ozarelix 68 CAMMS# 68 Phase III ADT 68 IMC A# 68 controlled multicenter Phase 68 LCP AtorFen 68 Phase III pivotal 68 CLORETAZINE TM VNP#M 68 dose cohorts 68 PIX# [002] 68 bortezomib Velcade 68 Phase #b/#a trial 68 cediranib 68 MGd 68 Phase 2b Clinical Trial 67 Allovectin 7 67 ALN VSP Phase 67 multicentre randomized 67 refractory CLL 67 GetGoal Phase III 67 HCV RESPOND 2 67 registrational Phase 67 tremelimumab 67 tanespimycin 67 gemcitabine Gemzar ® 67 ORMD 67 Alzhemed TM 67 Phase #b/#a clinical 67 CIMZIA TM 67 motesanib 67 TLK# 67 Enzastaurin 67 PSMA ADC 67 sorafenib Nexavar 67 ORACLE MS 67 oral rivaroxaban 67 prospective randomized placebo 67 EOquin TM 67 Dose escalation 67 CR# vcMMAE 67 romidepsin 67 CHAMPION PCI 67 midstage trials 67 treatment naïve genotype 67 antibody MAb 67 Phase 2b 67 albiglutide 67 confirmatory Phase 67 JAK inhibitor 67 MEND CABG 67 preclinical efficacy 67 AIR CF1 67 Vitaxin 67 BCIRG 67 bendamustine 67 huC# DM4 67 virus HCV protease inhibitor 67 SNT MC# 67 Plicera 67 multicenter dose escalation 67 Phase 2b clinical trials 67 placebo controlled randomized 67 Sapacitabine 67 relapsed refractory multiple myeloma 67 investigational protease inhibitor 67 TBC# 67 Urocidin 67 obatoclax 67 Phase III randomized 67 RG# [001] 67 PF # [002] 67 tolerated dose MTD 67 SCH # 67 prospective multicentre 67 Xelox 67 PEG PAL 67 AZILECT R 67 Hsp# Inhibitor 67 safety tolerability pharmacokinetic 67 OXi# 67 pain palliation 67 AEGR 67 IMPACT DCM 67 refractory chronic lymphocytic 67 Zenvia Phase III 67 Quinamed 67 Ceflatonin 67 initiate Phase IIb 67 Second Pivotal Phase 67 reslizumab 67 PFO migraine 66 LibiGel Phase III 66 docetaxel Taxotere R 66 IIa clinical trial 66 Tyrima 66 multicenter randomized controlled 66 Carfilzomib 66 Pivotal Phase II 66 teriflunomide 66 subcutaneous PRO 66 Zenvia ™ 66 CLL8 66 ZYBRESTAT fosbretabulin 66 PF # [001] 66 PRTX 66 LAF# 66 GAMMAGARD 66 randomized Phase 66 ZACTIMA 66 ENESTnd 66 Successfully Completes Phase 66 lintuzumab SGN 66 PDX pralatrexate 66 desvenlafaxine succinate 66 Archexin 66 Phase III Clinical Trials 66 pivotal Phase III 66 rindopepimut 66 subcutaneous methylnaltrexone 66 randomized blinded 66 IL# PE#QQR 66 PANVAC VF 66 Bezielle 66 ABSORB trial 66 EMPHASIS HF trial 66 pharmacodynamic effects 66 metastatic hormone refractory 66 KRN# 66 elacytarabine 66 RRMS patients 66 CLIRS 66 CLARITY study 66 ACTEMRA TM 66 liposomal formulation 66 Phase 2b randomized 66 oral deforolimus 66 trodusquemine 66 ENDEAVOR IV 66 ATL# [001] 66 label dose escalation 66 Phase III confirmatory 66 ILLUMINATE 66 evaluating mipomersen 66 CCR5 mAb 66 Capesaris 66 stated Michelle Berrey 66 generation purine nucleoside 66 NSABP 66 RhuDex 66 ENDEAVOR III 66 trastuzumab DM1 T DM1 66 estramustine 66 GSK# [002] 66 NSABP B 66 Zybrestat 66 HuMax CD4 66 Fx #A 66 randomized controlled multicenter 66 non nucleoside inhibitor 66 preclinical pharmacokinetic 66 ASA# 66 initiate Phase 2b 66 PEG SN# 66 AVOREN 66 Xanafide 66 Darusentan 66 NOX E# 66 biliary tract cancer 66 Meets Primary Endpoint 66 QLT# 66 OvaRex R 66 MEND CABG II 66 Dual Opioid 66 Panzem NCD 66 BAL# [002] 66 mapatumumab 66 cathepsin K inhibitor 66 celgosivir 66 CA4P 66 Mipomersen 66 glufosfamide 66 IMPACT IMmunotherapy 66 multicenter prospective 66 TACI Ig 66 UPLYSO 66 TRO# 66 ThermoDox R 66 ExTRACT TIMI 66 initiate Phase 1b 66 pharmacodynamics PD 66 SAR# [004] 66 Allovectin 7 ® 66 sorafenib Nexavar ® 66 controlled multicenter 66 TAXUS ATLAS 66 aplindore 66 Aclidinium 66 Phase Ib IIa 65 Triapine 65 novel histone deacetylase 65 PrevOnco 65 SUTENT ® 65 ospemifene 65 fostamatinib 65 CEQ# 65 TOLAMBA 65 dacetuzumab 65 label multicenter Phase 65 clinical trial 65 Randomized Phase II 65 Teriflunomide 65 Phase III Clinical Trial 65 PEARL SC 65 cannabinor 65 Omnitarg 65 Phase 2b kidney transplant 65 REG2 65 TASKi2 65 Dasatinib 65 Phase 65 Forodesine HCl 65 pivotal Phase 65 PDE4 inhibitor 65 PRESEPT 65 AVERROES 65 CALGB 65 AAG geldanamycin analog 65 APTIVUS 65 active comparator 65 PSN# [002] 65 anti leukemic 65 FOLOTYN ® 65 systemic ALCL 65 Corlux 65 oral antiviral 65 CALGB # [002] 65 systemic anaplastic large 65 CRLX# 65 PRE SURGE 65 oral picoplatin 65 baminercept 65 Apoptone 65 isavuconazole 65 oral FTY# 65 dosing cohorts 65 Safinamide 65 BNC# 65 Cloretazine R 65 OPT CHF 65 SPRYCEL ® 65 TMC# [002] 65 regorafenib 65 selective modulator 65 lorvotuzumab mertansine 65 EVEREST II 65 Ocrelizumab 65 HER2 positive metastatic breast 65 pharmacokinetics pharmacodynamics 65 cilengitide 65 bardoxolone 65 BrachySil TM 65 lumiliximab 65 HuMax CD# 65 Tanespimycin 65 Elagolix 65 prospective multicenter randomized 65 BR.# 65 assessing T DM1 65 initiate multicenter 65 IIb clinical trial 65 novel VDA molecule 65 prospectively defined 65 Degarelix 65 rilonacept 65 Kahalalide F 65 OncoVEX GM CSF 65 Pafuramidine 65 Pivotal Study 65 vemurafenib 65 ACTIVE W 65 PD LID 65 Afatinib 65 ZD# [001] 65 RezularTM 65 sorafenib tablets 65 blinded randomized 65 aclidinium bromide 65 docetaxel chemotherapy 65 ritonavir boosted danoprevir 65 Aryplase 65 nonrandomized 65 CAPACITY trials 65 ofatumumab 65 recurrent glioblastoma multiforme 65 Phase #/#a trial 65 pharmacokinetic pharmacodynamic 65 guanfacine extended release 65 sitaxsentan 65 Combination REOLYSIN R 65 samalizumab 65 EchoCRT 65 evaluating Prochymal 65 NSABP C 65 AQ4N 65 ToGA 65 randomized multicenter Phase III 65 amrubicin 65 Curaxin CBLC# 65 AKT inhibitor 65 tolevamer 65 Pivotal Trial 65 depsipeptide 65 refractory acute myeloid 65 HQK 65 relapsing remitting MS RRMS 65 Proellex TM 65 Thiovir 65 Androxal TM 65 RhuDex ® 65 ORENCIA ® 65 acyclovir Lauriad R 65 II Clinical Trial 65 KNS # 65 ritonavir boosted 65 Prospective Randomized 65 satraplatin Phase 65 Testosterone MDTS ® 65 icatibant 65 opioid induced bowel dysfunction 65 PNP inhibitor 65 posaconazole 65 Genz # 65 Asentar 65 Triapine R 65 brentuximab vedotin SGN 65 Maximum Tolerated Dose MTD 65 incyclinide 65 Phase IIb Trial 65 Spiegelmer ® 65 somatostatin analog 65 PRECISE Trial 65 pharmacokinetic studies 65 Aplidin R 65 Golimumab 65 vascular disrupting agent 65 EXPLORE Xa 65 deforolimus 65 Tasimelteon 65 Randomized Double blind 65 compound INCB# 65 Phase III HEAT 64 PRT# 64 Pharmacokinetic 64 multicenter placebo controlled 64 AZILECT ® 64 CCR5 antagonist 64 histone deacetylase HDAC inhibitor 64 bicifadine 64 multicenter randomized 64 Panzem R 64 orally inhaled migraine 64 ABSORB clinical 64 TEMSO 64 GW# [003] 64 CURE AF 64 LBH# 64 PRIMO CABG 64 Completes Patient Enrollment 64 Velcade bortezomib 64 CoFactor 64 OncoVex 64 Darinaparsin 64 figitumumab 64 CYT# potent vascular disrupting 64 LUMINATE 64 AP# [003] 64 PERSEUS 64 Lu AA# 64 ocrelizumab 64 DEB# 64 Denufosol 64 IMA# 64 Mylotarg 64 balsalazide tablet 64 omacetaxine mepesuccinate 64 PROSTVAC VF 64 interferon gamma 1b 64 Oglemilast 64 IND submission 64 solithromycin 64 Pazopanib 64 DLTs 64 prucalopride 64 heavily pretreated 64 pharmacodynamic markers 64 null responder HCV 64 plus prednisone prednisolone 64 R# #mg BID 64 dirucotide MBP# 64 non nucleoside HCV 64 Allovectin 7 R 64 valopicitabine 64 bosutinib 64 adjuvant colon cancer 64 Dose Ranging Study 64 LibiGel ® 64 recurrent metastatic 64 nitazoxanide 64 MGN# 64 dexpramipexole 64 evaluating Actimmune 64 intravenous dosing 64 Phase 2b monotherapy 64 ACCEDE 64 DCCR 64 ara C 64 EndoTAG TM -1 64 Diamyd r vaccine 64 dasatinib Sprycel ® 64 Phase III clinical trials 64 eprotirome 64 Glufosfamide 64 granted Ortec 64 demonstrated antitumor activity 64 TELCYTA 64 IMC #B 64 canakinumab 64 urocortin 2 64 Chemophase 64 ZYBRESTAT TM 64 temsirolimus 64 Vernakalant 64 huN# DM1 64 cariprazine 64 cytokine refractory 64 lead Aganocide compound 64 refractory cutaneous T 64 ZOLINZA 64 LibiGel testosterone gel 64 Multiple Ascending Dose 64 Phase Ib IIa clinical 64 AIR2 Trial 64 SYMMETRY trial 64 Vicriviroc 64 PEGylated interferon beta 1a 64 ofatumumab HuMax CD# 64 Diamyd ® 64 EGFR TKI 64 IAP inhibitor 64 landmark ATHENA 64 eltrombopag 64 RSD# 64 RE LY 64 Phase III trials 64 Blinatumomab 64 CML CP 64 Onconase 64 ascending doses 64 Pimavanserin 64 INSPIRE Trial Phase III 64 vicriviroc 64 prospective multicenter 64 Romidepsin 64 brivanib 64 Initiates Phase II 64 rNAPc2 64 Arranon 64 ASCEND HF 64 prospective randomized multicenter 64 eritoran 64 metaglidasen 64 IMGN# 64 RE SURGE 64 evaluating Nexavar 64 RhuDex R 64 COU AA 64 Pemetrexed 64 PI3K/Akt pathway inhibitor 64 CG# [003] 64 preclinically 64 tramiprosate ALZHEMED TM 64 pramlintide metreleptin combination 64 confirmatory Phase 3 64 TASKi3 64 YONDELIS R 64 Phase III LibiGel 64 safinamide 64 small molecule Hedgehog 64 inhaled AAT 64 CYT# QbG# 64 Troxatyl 64 NVA# 64 masked placebo controlled 64 ruxolitinib 64 tocilizumab 64 Silodosin 64 nucleotide analog 64 Fibrillex TM 64 enoximone capsules 64 vidofludimus 64 adecatumumab 64 multicentre 64 PHX# 64 Tarvacin TM 64 follicular Non Hodgkin 64 Intervention Effectiveness 64 Trastuzumab DM1 64 sargramostim 64 Hormone Refractory Prostate Cancer 64 antiviral efficacy 64 APEX AMI trial 64 Xeloda ® 64 clevidipine 64 nucleoside analog 64 LAB CGRP 64 FTY# fingolimod 64 CIMZIA TM certolizumab pegol 64 Phase lll 64 edoxaban 64 MVax 64 Hedgehog antagonist 64 Temsirolimus 64 pharmacodynamic properties 64 PRIMO CABG2 64 Fodosine 64 randomized multicentre 64 Tesetaxel 64 Cethromycin 64 imetelstat GRN#L 64 aflibercept 64 Diamyd r 64 triphendiol 64 GOUT 64 Trofex 64 orally bioavailable 64 lomitapide 64 EGS# 64 ANCHOR trial 64 phase III isavuconazole 64 #I TM# 64 BRAF inhibitor 64 AIR CF3 64 Akt inhibitor 64 tubulin inhibitor 64 HCV NS5B polymerase 64 selective androgen receptor modulator 64 methylnaltrexone 64 GRAVITAS trial 64 MGCD# [001] 64 sulodexide 64 Viramidine 64 MVax R 64 Maximum Tolerated Dose 63 initiate Phase Ib 63 refractory AML 63 HDAC Inhibitor 63 Ophena 63 lenalidomide Revlimid R 63 Phase IIb Clinical Trial 63 placebo controlled 63 efficacy endpoint 63 vernakalant hydrochloride 63 OMP #M# 63 resminostat 63 mitoxantrone plus 63 gefitinib Iressa 63 mg kg BID 63 eniluracil 63 MORAb 63 CALGB # [001] 63 seliciclib CYC# 63 tarenflurbil 63 Alocrest 63 metastatic HRPC 63 CUSTOM III 63 TELINTRA 63 BOLDER II 63 MDS AML 63 GLPG# 63 Bicifadine 63 Actilon 63 trastuzumab emtansine T DM1 63 Aurora Kinase 63 LEP ETU 63 PROSTVAC ® 63 Phase III ALLEGRO 63 Randomised 63 Clinical Antipsychotic Trials 63 ularitide 63 Targretin capsules 63 davunetide intranasal AL 63 AVASTIN 63 DSMB recommended 63 acute mania 63 Ixempra 63 BrachySil 63 Pharmacodynamic 63 alvimopan 63 tolerability 63 Phase 2b Trial 63 dirucotide 63 CINQUIL 63 weekly subcutaneous injections 63 ADAGIO study 63 MT#/MEDI-# 63 MyVax personalized immunotherapy 63 cisplatin gemcitabine 63 BioNumerik 63 refractory CTCL 63 Motesanib 63 LymphoStat B belimumab 63 SIMPADICO 63 dependent kinase inhibitor 63 BCX# 63 Personalized Immunotherapy 63 DU #b 63 evaluating T DM1 63 unblinding 63 Phase IIIb study 63 gallium nitrate 63 EDEMA3 trial 63 TPI ASM8 63 pharmacodynamic profile 63 Phase 2b Study 63 low dose cytarabine 63 tezampanel NGX# 63 receptor inhibitor 63 Achieves Primary Endpoint 63 Phase III TRIST 63 relapsed multiple myeloma 63 Medullary Thyroid Cancer 63 severe hypercholesterolemia 63 prospective observational 63 afatinib 63 crizotinib PF # 63 CATIE AD 63 randomized placebo controlled 63 multicenter randomized double 63 Clinical Trial Results 63 Nuvion 63 PEG IFN 63 Benlysta belimumab 63 OHR/AVR# 63 multicentre phase 63 5 fluorouracil leucovorin 63 MEK inhibitor 63 ancrod 63 dexanabinol 63 evaluating REVLIMID 63 GV# [001] 63 Vectibix panitumumab 63 ORAL Sync 63 EURIDIS 63 VICTOR E1 63 recurrent malignant glioma 63 ALB # 63 ONCONASE R 63 APTIVUS r 63 PROSTVAC TM 63 lucinactant 63 RGB # 63 Laquinimod 63 optimal dosing regimens 63 eosinophilic asthma 63 Myocet 63 Folfox 63 iclaprim 63 GRN# 63 relapsed myeloma 63 XmAb# 63 TO AVOID PREGNANCY WHILE 63 placebo controlled dose escalation 63 fluticasone furoate 63 unique alkylating agent 63 RhuDex TM 63 EOquin 63 SPIRIT FIRST 63 Tarvacin Anti Cancer 63 ACAPODENE 63 thalidomide Thalomid 63 Vidaza azacitidine 63 Dapagliflozin 63 single ascending dose 63 Q#IR 63 evaluating satraplatin 63 Triolex 63 multicenter multinational 63 Iloperidone 63 varespladib 63 investigational humanized monoclonal antibody 63 atacicept 63 alemtuzumab Campath 63 ASSERT trial 63 ataluren 63 talabostat 63 NEO3 63 Sorafenib HCC Assessment 63 administered subcutaneously 63 Cimzia ® certolizumab pegol 63 otelixizumab 63 RELOVAIR ™ 63 cell lymphoma CTCL 63 MIRCERA 63 HuLuc# 63 placebo controlled studies 63 previously untreated follicular 63 Antiviral Activity 63 Tesmilifene 63 Virulizin ® 63 apoptosis inducer 63 PEG Interferon lambda 63 zalutumumab 63 oral COTI 63 pharmacodynamic 63 Commences Phase 63 TransVax TM 63 de novo kidney transplant 63 REVIVE TA 63 iniparib 63 docetaxel Taxotere ® 63 genotypic resistance 63 tolerability profiles 63 REMINYL ® 63 pharmacokinetic 63 Ceflatonin R 63 phase III ACCLAIM 63 NABTT 63 secondary efficacy endpoints 63 standard chemotherapy regimen 63 Pirfenidone 63 blind randomized placebo 63 BLA filing 63 Synta Announces 63 APF# Phase 63 MKC# MT 63 ganaxolone 63 entinostat 63 Plenaxis TM 63 includes TOLAMBA TM 63 oral Xeloda 63 bepotastine besilate nasal spray 63 clevudine 63 ZK EPO 63 REOLYSIN ® 63 apremilast 63 PrevOnco ™ 63 mGluR5 NAM 63 vosaroxin 63 telaprevir VX 63 Genasense oblimersen sodium Injection 63 PRX # 63 CCX# B 63 Cannabinor 63 placebo controlled clinical trials 63 adipiplon 63 PhG alpha 1 63 Tipranavir 63 novel chimeric natriuretic 63 EDEMA3 63 Phase III Trial 63 zanolimumab 63 Ambrisentan 63 CELVAPAN H#N# 63 carfilzomib 63 sunitinib 63 Amigal 63 Evoltra ® 63 EndoTAGTM 1 63 ChronVac C ® 63 Crofelemer budesonide foam 63 Clolar ® 63 Solorel 63 generation PNP inhibitor 63 Pharmacokinetics PK 63 VIRAMUNE XR 63 paclitaxel Taxol R 63 ENMD # 63 randomized controlled clinical 63 RECORD1 63 Epratuzumab 63 Tocosol Paclitaxel 63 Zoraxel 63 PPAR gamma agonist 63 Pharmacokinetic Study 63 vinflunine 63 MVA MUC1 IL2 63 nitric oxide donating prostaglandin 63 dose regimens 63 subcutaneous formulation 63 SYN# 62 BIBW 62 next generation URAT1 62 TORISEL TM